U.S. President Donald Trump has been advocating the use of malaria treatment for COVID-19 patients, calling it to be a “game changer” in fighting the virus. But the use of hydroxychloroquine has once again failed to show any positive effect on the COVID-19 patients hospitalized for the treatment, a study revealed on Thursday.

The study was published in the New England Journal of Medicine under certain limitations in which the doctors reported that the use of the drug could neither lessen the need for breathing assistance of the inmates nor did it control the death risks. “We didn’t see any association between getting this medicine and the chance of dying or being intubated,” Dr. Neil Schluger, the lead researcher, told Reuters during a telephonic interview. “The patients who got the drug didn’t seem to do any better.”

In April, doctors at the U.S. Department of Veterans Affairs stated that hydroxychloroquine did not help the Coronavirus patients; instead, it is likely to impose a higher risk of death. The death rate based on this analysis accounted for 28% of fatalities when the drug was mixed with the standard treatment, while the rate was only 11% for the patients who received the conventional treatments alone.

However, in the recent instance, the doctors preferred giving the drug to sicker patients due to which the researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center adjusted the rate of the drug accordingly. The doctors here confirmed that hydroxychloroquine did not help the patients clearly, but then they also agreed that the drug may not have imposed any negative effect to have hurt them.

In the process, 32.3% of patients who were given the drug began requiring a ventilator or ended up dying compared to the 14.9% patients who were not given the drug and did not show such rapid destruction.

Hydroxychloroquine has also been a decade old treatment for lupus and rheumatoid arthritis. However, Schluger’s team reported that the same drug, even when combined with antibiotic azithromycin, did not show any benefit to the health of COVID-19 patients.

The researchers said that the benefit or harm should not be taken to rule based on the study as for now, but then the lead researcher Schluger added that doctors wouldn’t recommend giving hydroxychloroquine to hospitalized patients any more depending on the change in the hospital guidelines.